Napo Pharmaceuticals appoints new chief medical officer


Gastrointestinal pharmaceutical company Napo Pharmaceuticals recently introduced Darlene Horton, MD, as its new chief medical officer, according to a May 26 press release.

In her new role, Dr. Horton will support the company in its phase 3 clinical trial of its crofelemer drug meant to prevent diarrhea in cancer patients receiving cancer therapy.

Dr. Horton received her medical degree from the University of Florida in Gainesville and completed a residency and fellowship at the University of California San Francisco. She has previous leadership experience at various healthcare companies, including being the CMO of Coherus BioSciences, Itero Biopharmaceuticals and SMC Biotechnology.

Napo Pharmaceuticals is a subsidiary of Jaguar Health, based in San Francisco.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers